Opendata, web and dolomites

NeutroCure SIGNED

Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeutroCure project word cloud

Explore the words cloud of the NeutroCure project. It provides you a very rough idea of what is the project "NeutroCure" about.

mechanisms    spatial    species    nature    generation    first    reverse    neutrophil    pharmaceutical    consists    normal    solutions    contributes    patient    solution    ros    abnormal    killing    modulation    polymorphonuclear    tissues    unexplored    functions    activation    boosting    cell    time    temporal    sme    cells    amplifiers    leads    breakthrough    realized    nets    precise    neutrocure    myeloablation    previously    possibilities    trigger    redox    aberrant    inflammation    extracellular    drug    regulation    drugs    neutrophils    academic    paradox    attempt    chemotherapy    safe    radio    autoimmunity    oxygen    organism    uncontrolled    society    caused    prodrug    dysregulated    commercialization    settings    damaging    innovative    pathological    relieve    pathologic    cure    concentration    resolution    haematopoiesis    positive    treatment    cancer    disturbance    causes    signaling    healthy    traps    phenotype    occurs    despite    reactive    multiple    proximal    severe    clinical    inhibits    space    deactivation   

Project "NeutroCure" data sheet

The following table provides information about the project.

Coordinator
FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG 

Organization address
address: SCHLOSSPLATZ 4
city: ERLANGEN
postcode: 91054
website: www.uni-erlangen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙999˙998 €
 EC max contribution 2˙999˙998 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-2018-2019-2020-01
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG DE (ERLANGEN) coordinator 629˙000.00
2    UNIVERSITATSKLINIKUM ERLANGEN DE (ERLANGEN) participant 640˙000.00
3    UNIVERSITY OF SURREY UK (GUILDFORD) participant 410˙998.00
4    CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) ES (MADRID) participant 400˙000.00
5    LVIVSKYI NATIONALNYI MEDYCHNYI UNIVERSYTET IMENI DANYLA HALYTSKOHO UA (LVIV) participant 400˙000.00
6    REDOXIS AB SE (LUND) participant 400˙000.00
7    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 120˙000.00

Map

 Project objective

Reactive oxygen species (ROS) have key functions in healthy organism such as redox signaling for regulation of cell growth, triggering formation of neutrophil extracellular traps (NETs), and modulation of inflammation. Since in high concentration ROS are damaging to tissues, nature has evolved precise mechanisms to control their generation at the required time, concentration and space, proximal to their target. Disturbance of these mechanisms leads to aberrant ROS production that causes uncontrolled inflammation, occurs in myeloablation caused by radio- or chemotherapy and is a crucial feature of cancer cell phenotype as well as autoimmunity. Despite the damaging properties of ROS it is a paradox that pharmaceutical ROS amplifiers can reverse (“cure”) many pathologic features. For example, ROS-induced cancer cell killing inhibits cancer growth, ROS-induced deactivation of T-cells and NETs generation contributes to resolution of inflammation, and ROS-induced boosting of haematopoiesis can relieve myeloablation. These exciting possibilities have not been realized in clinical settings yet, since the high level of temporal and spatial control of ROS generation, required to allow for safe patient treatment, has yet not been achieved for any known drug. NeutroCure will be the first attempt to achieve a breakthrough solution to this problem. Using an innovative approach based on the multiple-trigger prodrug activation, this consortium will develop safe ROS amplifiers capable of boosting ROS specifically in abnormal polymorphonuclear neutrophils associated with cancer, uncontrolled inflammation and relevant for myeloablation without affecting normal cells. NeutroCure consists of 6 European academic partners and an SME who will promote commercialization of the new drugs. We expect that this project will have a great positive impact on the Society by providing previously unexplored treatment solutions for severe pathological conditions caused by dysregulated ROS-production.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUTROCURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUTROCURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

EDRA (2019)

Hardware-Assisted Decoupled Access Execution on the Digital Market: The EDRA Framework

Read More  

FLIX (2020)

FLow chemistry for Isotopic eXchange

Read More  

LABELFREE (2019)

LABEL FREE IMAGING WITH PHI-SCAT

Read More